| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,000 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$50,778 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-04-01 |
4 |
D |
$3.08 |
$484 |
D/D |
(157) |
133,741 |
|
- |
|
| Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-01 |
4 |
D |
$3.08 |
$290 |
D/D |
(94) |
131,743 |
|
- |
|
| Domzalski David |
PRESIDENT AND CEO |
• • – |
2024-04-01 |
4 |
D |
$3.08 |
$3,092 |
D/D |
(1,004) |
494,160 |
|
- |
|
| Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
• – – |
2024-04-01 |
4 |
D |
$3.08 |
$496 |
D/D |
(161) |
149,274 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2024-01-02 |
4 |
D |
$2.28 |
$358 |
D/D |
(157) |
133,898 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2024-01-02 |
4 |
D |
$2.28 |
$2,289 |
D/D |
(1,004) |
495,164 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
D |
$2.28 |
$212 |
D/D |
(93) |
131,837 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2024-01-02 |
4 |
D |
$2.28 |
$367 |
D/D |
(161) |
149,435 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
134,055 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
225,000 |
496,168 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
131,930 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
149,596 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
71,555 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
69,430 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
87,096 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
225,000 |
271,168 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2023-11-30 |
4 |
A |
$2.81 |
$6,426 |
D/D |
2,284 |
46,168 |
|
- |
|
| Lepore Patrick G |
Director |
– • – |
2023-11-15 |
4 |
B |
$3.91 |
$50,778 |
D/D |
13,000 |
36,472 |
2.39 |
- |
|
| Blavatnik Len |
10% Owner |
– – • |
2023-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,116,585 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2023-10-02 |
4 |
D |
$3.83 |
$4,163 |
D/D |
(1,087) |
6,930 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2023-10-02 |
4 |
D |
$3.83 |
$4,420 |
D/D |
(1,154) |
24,596 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2023-10-02 |
4 |
D |
$3.83 |
$4,535 |
D/D |
(1,184) |
9,055 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2023-10-02 |
4 |
D |
$3.83 |
$32,743 |
D/D |
(8,549) |
43,884 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2023-06-30 |
4 |
D |
$4.10 |
$4,022 |
D/D |
(981) |
52,433 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2023-06-30 |
4 |
D |
$4.10 |
$644 |
D/D |
(157) |
25,750 |
|
- |
|
165 Records found
|
|
Page 1 of 7 |
|
|
